Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Other Non-Current Liabilities (2024 - 2025)

Evommune (EVMN) has disclosed Other Non-Current Liabilities for 2 consecutive years, with $261000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Non-Current Liabilities changed N/A to $261000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $261000.0, a N/A change, with the full-year FY2024 number at $535000.0, changed N/A from a year prior.
  • Other Non-Current Liabilities was $261000.0 for Q3 2025 at Evommune, down from $535000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $535000.0 in Q4 2024 to a low of $261000.0 in Q3 2025.